Paper Details
- Home
- Paper Details
Multicenter, randomized study of the effectiveness of basiliximab in avoiding addition of steroids to cyclosporine a monotherapy in renal transplant recipients.
Author: AndrewsChristopher D, HammadAbdel Q, LodgeJ Peter A, ParrottNeil R, WatsonChristopher J E
Original Abstract of the Article :
BACKGROUND: Steroid therapy is associated with an increased risk of cardiovascular events and well-documented adverse effects, but two thirds of patients initiated on monotherapy with cyclosporine A (CsA) microemulsion require addition of steroids. METHODS: In this 12-month randomized, double-blind...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://doi.org/10.1097/01.tp.0000151006.86197.76
データ提供:米国国立医学図書館(NLM)
Basiliximab Induction: A Strategy to Avoid Steroids in Renal Transplant Recipients
Organ transplantation is a life-saving procedure, but it often requires a complex regimen of immunosuppressive medications to prevent rejection. This multicenter, randomized study explores the potential of basiliximab induction to reduce the need for steroids in renal transplant recipients. The study aims to identify a safer and more effective approach to immunosuppression, much like a desert traveler seeking a more efficient and sustainable route through a challenging landscape.
Evaluating the Effectiveness of Basiliximab Induction in Renal Transplant
The authors demonstrate that basiliximab induction significantly reduces the need for additional immunosuppression, including steroids, in renal transplant recipients. This finding suggests that basiliximab may be a valuable strategy for avoiding the potential side effects of steroids.
Improving Outcomes for Renal Transplant Recipients
This research highlights the potential for improving outcomes for renal transplant recipients through targeted and individualized immunosuppression. It's like a camel caravan adapting to the changing conditions of the desert: understanding the specific needs of each member of the caravan and tailoring the journey accordingly.
Dr.Camel's Conclusion
This study is a significant contribution to the field of renal transplantation. It shows that basiliximab induction can effectively reduce the need for steroids, potentially leading to better long-term outcomes for transplant recipients. It's like finding a hidden oasis: a source of hope and a potential solution to a challenging problem.
Date :
- Date Completed 2005-03-22
- Date Revised 2019-07-13
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.